Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 20;11(1):41. doi: 10.1038/s41419-020-2232-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, b The effect of FOXD2-AS1 expression level on tumor formation during cisplatin treatment. Tumor growth curves a of mice injected with indicated cells were established after treated with cisplatin since 14 dpi. Mice planted with vector cells serve as controls. Subcutaneous tumors were collected a and the tumor weights b were recorded at the end point of this study. As showed in the figures, FOXD2-AS1-overexpressing cells had stronger tumor formation potential than control cells during cisplatin treatment. Representative IHC staining c of Ki67 and TUNEL staining d in paraffin-embedded specimens from the subcutaneous tumors showed significant increased Ki67 level and decreased apoptosis level in FOXD2-AS1-overexpressing cells; n = 6/group; dpi days post inoculation. *P < 0.05, **P < 0.01, and ***P < 0.001.